Mouthwash for eradicating oral H. pylori infection
MAXPOWER Biological Antibacterial Liquid Oral Helicobacter Pylori Eradication Evaluation
This study is testing a new mouthwash to see if it can help people aged 18-70 get rid of oral H. pylori infection when traditional antibiotics don't work.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 42 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Changhai Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT06045832 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of MAXPOWER Biological Antibacterial mouthwash in eradicating oral Helicobacter pylori (H. pylori) in patients aged 18-70 who test positive for the bacteria. Traditional antibiotic therapies have proven ineffective against oral H. pylori, necessitating the development of an antibiotic-free mouthwash. Participants will be recruited from Changhai Hospital, and their eligibility will be determined through a saliva test for H. pylori. The study aims to provide a safer and more effective alternative for treating oral H. pylori infections.
Who should consider this trial
Good fit: Ideal candidates are oral H. pylori-positive patients aged 18-70 who are visiting the outpatient clinic of Changhai Hospital.
Not a fit: Patients with significant gastrointestinal conditions or serious concomitant illnesses will not benefit from this study.
Why it matters
Potential benefit: If successful, this mouthwash could provide a non-antibiotic solution for patients suffering from oral H. pylori infections, reducing the risk of antibiotic resistance.
How similar studies have performed: While traditional methods have struggled with oral H. pylori, this approach is novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:Oral H. pylori-positive patients, verified by H. pylori saliva test (HPS),aged 18-70 years visiting the outpatient clinic of Changhai Hospital from March 1, 2023, to August 1, 2023, were enrolled. Exclusion Criteria: (1) Zollinger-Ellison syndrome, gastric cancer, upper gastrointestinal bleeding, or active peptic ulcer; (2) the coexistence of significant concomitant illnesses, including heart diseases, renal failure, hepatic disease, previous abdominal surgery, lactation or pregnancy; and (3) not willing to participate in the study. -
Where this trial is running
Shanghai, Shanghai
- Changhai hospital — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Yongkang Lai, Dr.
- Email: 4090275844@qq.com
- Phone: +86-18270881495
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.